Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.32 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215500 | 0.88 | AAK1 (0.37) | AAK1PRMT5WDR77 | |
| SCHEMBL17367471 | 0.80 | CSF1R (0.37) | LIPGLPLHIF1APDGFRBKDR | |
| SCHEMBL17367468 | 0.80 | SLC6A3 (0.35) | AAK1 | |
| SCHEMBL15912465 | 0.78 | LIPG (0.53) | LIPGLPL | |
| SCHEMBL14790503 | 0.76 | LIPG (0.45) | LIPGLPL | |
| SCHEMBL15854185 | 0.74 | OPRM1 (0.41) | — | |
| SCHEMBL16113878 | 0.73 | BACE1 (0.49) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL17367477 | 0.73 | PTGS1 (0.32) | — | |
| SCHEMBL25235246 | 0.72 | AAK1 (0.46) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL2362943 | 0.72 | AAK1 (0.45) | AAK1PRMT5WDR77BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | AAK1 1949/4885PRMT5 1798/4885WDR77 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.